Akero Therapeutics (AKRO) announced that it has commenced an underwritten public offering of $300M of shares of its common stock. All of the shares in the proposed offering are being offered by Akero. J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Madrigal dip on Akero data a buying opportunity, says Evercore ISI
- China’s DeepSeek sinks tech, AT&T reports Q4 beat: Morning Buzz
- H.C. Wainwright ups Akero target after ‘ground-breaking’ data
- H.C. Wainwright upgrades Akero target after ‘ground-breaking’ data
- Akero Therapeutics Reports Promising Phase 2b Study Results